• Explore /
  • Poster
  • / Larotrectinib (laro) long-term efficacy and safety in patients (pts) with tropomyosin receptor kinase (TRK) fusion thyroid carcinoma (TC).

Larotrectinib (laro) long-term efficacy and safety in patients (pts) with tropomyosin receptor kinase (TRK) fusion thyroid carcinoma (TC).

Abstract Poster

Authors

null

Maria E. Cabanillas

The University of Texas MD Anderson Cancer Center, Houston, TX

Maria E. Cabanillas , Jessica Jiyeong Lin , Marcia S. Brose , Raymond S. McDermott , Mohammed Almubarak , Jessica R Bauman , Michela Casanova , Shivaani Kummar , Se-Hoon Lee , Serge Leyvraz , Do-Youn Oh , Lin Shen , Ricarda Norenberg , Vadim Bernard-Gauthier , Chiara E. Mussi , David S. Hong , Alexander E. Drilon , Steven G. Waguespack

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Head and Neck Cancer

Track

Head and Neck Cancer

Sub Track

Other Head and Neck Cancer (Salivary, Thyroid)

Clinical Trial Registration Number

NCT02576431, NCT02122913, NCT02637687

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 6091)

DOI

10.1200/JCO.2023.41.16_suppl.6091

Abstract #

6091

Poster Bd #

83

Abstract Disclosures

Similar Posters

First Author: Alexander E. Drilon

First Author: David S. Hong

First Author: Leo Mascarenhas

First Author: Jessica Jiyeong Lin